{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,3]],"date-time":"2026-04-03T03:22:47Z","timestamp":1775186567423,"version":"3.50.1"},"reference-count":37,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2018,12,1]],"date-time":"2018-12-01T00:00:00Z","timestamp":1543622400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,12,1]],"date-time":"2018-12-01T00:00:00Z","timestamp":1543622400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,6,8]],"date-time":"2022-06-08T00:00:00Z","timestamp":1654646400000},"content-version":"vor","delay-in-days":1285,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/501100008667","name":"SENSHIN Medical Research Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100008667","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81671584"],"award-info":[{"award-number":["81671584"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","exphem.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Experimental Hematology"],"published-print":{"date-parts":[[2018,12]]},"DOI":"10.1016\/j.exphem.2018.09.001","type":"journal-article","created":{"date-parts":[[2018,9,5]],"date-time":"2018-09-05T14:30:46Z","timestamp":1536157846000},"page":"80-88.e2","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":20,"special_numbering":"C","title":["miR-217 sensitizes chronic myelogenous leukemia cells to tyrosine kinase inhibitors by targeting pro-oncogenic anterior gradient 2"],"prefix":"10.1016","volume":"68","author":[{"given":"Bin","family":"Pan","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jing","family":"Yang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiangmin","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1375-1084","authenticated-orcid":false,"given":"Kailin","family":"Xu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takayuki","family":"Ikezoe","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.exphem.2018.09.001_bib0001","first-page":"751","article-title":"The molecular biology of chronic myeloid leukaemia","volume":"10","author":"Melo","year":"1996","journal-title":"Leukemia"},{"key":"10.1016\/j.exphem.2018.09.001_bib0002","doi-asserted-by":"crossref","first-page":"11746","DOI":"10.1073\/pnas.92.25.11746","article-title":"The Bcr-Abl leukemia oncogene activates Jun kinase and requires Jun for transformation","volume":"92","author":"Raitano","year":"1995","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.exphem.2018.09.001_bib0003","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1002\/ajh.24249","article-title":"Chronic myeloid leukemia: First-line drug of choice","volume":"91","author":"Jabbour","year":"2016","journal-title":"Am J Hematol"},{"key":"10.1016\/j.exphem.2018.09.001_bib0004","doi-asserted-by":"crossref","first-page":"1783","DOI":"10.1056\/NEJMoa1306494","article-title":"A phase 2 trial of ponatinib in Philadelphia chromosome-positive leukemias","volume":"369","author":"Cortes","year":"2013","journal-title":"N Engl J Med"},{"key":"10.1016\/j.exphem.2018.09.001_bib0005","doi-asserted-by":"crossref","first-page":"1852","DOI":"10.1056\/NEJMe1311325","article-title":"Overcoming resistance to targeted anticancer drugs","volume":"369","author":"Doroshow","year":"2013","journal-title":"N Engl J Med"},{"key":"10.1016\/j.exphem.2018.09.001_bib0006","doi-asserted-by":"crossref","first-page":"1631","DOI":"10.1038\/leu.2010.145","article-title":"Long-term exposure of leukemia cells to multi\u2013targeted tyrosine kinase inhibitor induces activations of AKT, ERK and STAT5 signaling via epigenetic silencing of the PTEN gene","volume":"24","author":"Nishioka","year":"2010","journal-title":"Leukemia"},{"key":"10.1016\/j.exphem.2018.09.001_bib0007","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1111\/cas.12339","article-title":"Downregulation of miR\u2013217 correlates with resistance of Ph(+) leukemia cells to ABL tyrosine kinase inhibitors","volume":"105","author":"Nishioka","year":"2014","journal-title":"Cancer Sci"},{"key":"10.1016\/j.exphem.2018.09.001_bib0008","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1172\/JCI35721","article-title":"Human chronic myeloid leukemia stem cells are insensitive to imatinib despite inhibition of BCR-ABL activity","volume":"121","author":"Corbin","year":"2011","journal-title":"J Clin Invest"},{"key":"10.1016\/j.exphem.2018.09.001_bib0009","doi-asserted-by":"crossref","first-page":"1719","DOI":"10.1038\/leu.2010.185","article-title":"Patients with chronic myeloid leukemia who maintain a complete molecular response after stopping imatinib treatment have evidence of persistent leukemia by DNA PCR","volume":"24","author":"Ross","year":"2010","journal-title":"Leukemia"},{"key":"10.1016\/j.exphem.2018.09.001_bib0010","doi-asserted-by":"crossref","first-page":"2499","DOI":"10.1038\/onc.2012.346","article-title":"Emerging roles for the pro-oncogenic anterior gradient-2 in cancer development","volume":"32","author":"Chevet","year":"2013","journal-title":"Oncogene"},{"key":"10.1016\/j.exphem.2018.09.001_bib0011","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1074\/mcp.M300089-MCP200","article-title":"The Barrett's antigen anterior gradient-2 silences the p53 transcriptional response to DNA damage","volume":"3","author":"Pohler","year":"2004","journal-title":"Mol Cell Proteomics"},{"key":"10.1016\/j.exphem.2018.09.001_bib0012","doi-asserted-by":"crossref","first-page":"44855","DOI":"10.1074\/jbc.M111.275529","article-title":"Role of pro-oncogenic protein disulfide isomerase (PDI) family member anterior gradient 2 (AGR2) in the control of endoplasmic reticulum homeostasis","volume":"286","author":"Higa","year":"2011","journal-title":"J Biol Chem"},{"key":"10.1016\/j.exphem.2018.09.001_bib0013","doi-asserted-by":"crossref","first-page":"91","DOI":"10.3858\/emm.2011.43.2.011","article-title":"AGR2, a mucinous ovarian cancer marker, promotes cell proliferation and migration","volume":"43","author":"Park","year":"2011","journal-title":"Exp Mol Med"},{"key":"10.1016\/j.exphem.2018.09.001_bib0014","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1158\/0008-5472.CAN-07-2930","article-title":"The adenocarcinoma-associated antigen, AGR2, promotes tumor growth, cell migration, and cellular transformation","volume":"68","author":"Wang","year":"2008","journal-title":"Cancer Res"},{"key":"10.1016\/j.exphem.2018.09.001_bib0015","doi-asserted-by":"crossref","first-page":"3796","DOI":"10.1158\/0008-5472.CAN-04-3823","article-title":"Human homologue of cement gland protein, a novel metastasis inducer associated with breast carcinomas","volume":"65","author":"Liu","year":"2005","journal-title":"Cancer Res"},{"key":"10.1016\/j.exphem.2018.09.001_bib0016","doi-asserted-by":"crossref","first-page":"7696","DOI":"10.1158\/0008-5472.CAN-08-4901","article-title":"Identification of candidate biomarkers of therapeutic response to docetaxel by proteomic profiling","volume":"69","author":"Zhao","year":"2009","journal-title":"Cancer Res"},{"key":"10.1016\/j.exphem.2018.09.001_bib0017","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1016\/j.canlet.2013.06.025","article-title":"Anterior gradient 2: a novel sensitive tumor marker for metastatic oral cancer","volume":"339","author":"Chen","year":"2013","journal-title":"Cancer Lett"},{"key":"10.1016\/j.exphem.2018.09.001_bib0018","doi-asserted-by":"crossref","first-page":"1848","DOI":"10.2353\/ajpath.2009.090246","article-title":"The metastasis-associated anterior gradient 2 protein is correlated with poor survival of breast cancer patients","volume":"175","author":"Barraclough","year":"2009","journal-title":"Am J Pathol"},{"key":"10.1016\/j.exphem.2018.09.001_bib0019","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1038\/sj.pcan.4500960","article-title":"Increased expression of anterior gradient-2 is significantly associated with poor survival of prostate cancer patients","volume":"10","author":"Zhang","year":"2007","journal-title":"Prostate Cancer Prostatic Dis"},{"key":"10.1016\/j.exphem.2018.09.001_bib0020","doi-asserted-by":"crossref","first-page":"4838","DOI":"10.1038\/onc.2010.228","article-title":"The pro-metastatic protein anterior gradient-2 predicts poor prognosis in tamoxifen-treated breast cancers","volume":"29","author":"Hrstka","year":"2010","journal-title":"Oncogene"},{"key":"10.1016\/j.exphem.2018.09.001_bib0021","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1016\/j.canlet.2013.01.034","article-title":"Identification of an AKT-dependent signalling pathway that mediates tamoxifen-dependent induction of the pro-metastatic protein anterior gradient-2","volume":"333","author":"Hrstka","year":"2013","journal-title":"Cancer Lett"},{"key":"10.1016\/j.exphem.2018.09.001_bib0022","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1038\/nrg1379","article-title":"MicroRNAs: small RNAs with a big role in gene regulation","volume":"5","author":"He","year":"2004","journal-title":"Nat Rev Genet"},{"key":"10.1016\/j.exphem.2018.09.001_bib0023","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1016\/j.cell.2009.02.005","article-title":"MicroRNAs and cancer: short RNAs go a long way","volume":"136","author":"Ventura","year":"2009","journal-title":"Cell"},{"key":"10.1016\/j.exphem.2018.09.001_bib0024","article-title":"MicroRNA regulation of K-Ras in pancreatic cancer and opportunities for therapeutic intervention","author":"Karmakar","year":"2017","journal-title":"Semin Cancer Biol"},{"key":"10.1016\/j.exphem.2018.09.001_bib0025","doi-asserted-by":"crossref","first-page":"4359","DOI":"10.1158\/1078-0432.CCR-13-0980","article-title":"Contribution of ABCC4-mediated gastric transport to the absorption and efficacy of dasatinib","volume":"19","author":"Furmanski","year":"2013","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.exphem.2018.09.001_bib0026","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1038\/bmt.2016.195","article-title":"The fifth epidermal growth factor-like region of thrombomodulin exerts cytoprotective function and prevents SOS in a murine model","volume":"52","author":"Ikezoe","year":"2017","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.exphem.2018.09.001_bib0027","doi-asserted-by":"crossref","first-page":"e48","DOI":"10.1038\/bcj.2011.33","article-title":"Imatinib causes epigenetic alterations of PTEN gene via upregulation of DNA methyltransferases and polycomb group proteins","volume":"1","author":"Nishioka","year":"2011","journal-title":"Blood Cancer J"},{"key":"10.1016\/j.exphem.2018.09.001_bib0028","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1016\/j.ccr.2014.07.006","article-title":"BCR-ABL1 compound mutations combining key kinase domain positions confer clinical resistance to ponatinib in Ph chromosome-positive leukemia","volume":"26","author":"Zabriskie","year":"2014","journal-title":"Cancer Cell"},{"key":"10.1016\/j.exphem.2018.09.001_bib0029","doi-asserted-by":"crossref","first-page":"1493","DOI":"10.1038\/leu.2016.51","article-title":"A role for FOXO1 in BCR-ABL1-independent tyrosine kinase inhibitor resistance in chronic myeloid leukemia","volume":"30","author":"Wagle","year":"2016","journal-title":"Leukemia"},{"key":"10.1016\/j.exphem.2018.09.001_bib0030","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1158\/1078-0432.CCR-16-0226","article-title":"Anthelmintic niclosamide disrupts the interplay of p65 and FOXM1\/beta-catenin and eradicates leukemia stem cells in chronic myelogenous leukemia","volume":"23","author":"Jin","year":"2017","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.exphem.2018.09.001_bib0031","doi-asserted-by":"crossref","first-page":"2324","DOI":"10.1002\/stem.1748","article-title":"The antiproliferative activity of kinase inhibitors in chronic myeloid leukemia cells is mediated by FOXO transcription factors","volume":"32","author":"Pellicano","year":"2014","journal-title":"Stem Cells"},{"key":"10.1016\/j.exphem.2018.09.001_bib0032","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.canlet.2010.12.023","article-title":"Anterior gradient 2: a novel player in tumor cell biology","volume":"304","author":"Brychtova","year":"2011","journal-title":"Cancer Lett"},{"key":"10.1016\/j.exphem.2018.09.001_bib0033","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1002\/pros.22569","article-title":"Anterior gradient 2 (AGR2): blood-based biomarker elevated in metastatic prostate cancer associated with the neuroendocrine phenotype","volume":"73","author":"Kani","year":"2013","journal-title":"Prostate"},{"key":"10.1016\/j.exphem.2018.09.001_bib0034","doi-asserted-by":"crossref","first-page":"R32","DOI":"10.1186\/bcr2586","article-title":"Anterior gradient-2 plays a critical role in breast cancer cell growth and survival by modulating cyclin D1, estrogen receptor-alpha and survivin","volume":"12","author":"Vanderlaag","year":"2010","journal-title":"Breast Cancer Res"},{"key":"10.1016\/j.exphem.2018.09.001_bib0035","doi-asserted-by":"crossref","first-page":"18301","DOI":"10.1074\/jbc.M110.215707","article-title":"The human adenocarcinoma-associated gene, AGR2, induces expression of amphiregulin through Hippo pathway co-activator YAP1 activation","volume":"286","author":"Dong","year":"2011","journal-title":"J Biol Chem"},{"key":"10.1016\/j.exphem.2018.09.001_bib0036","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1172\/JCI35660","article-title":"Targeting autophagy potentiates tyrosine kinase inhibitor-induced cell death in Philadelphia chromosome-positive cells, including primary CML stem cells","volume":"119","author":"Bellodi","year":"2009","journal-title":"J Clin Invest"},{"key":"10.1016\/j.exphem.2018.09.001_bib0037","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1186\/s12943-016-0518-2","article-title":"Clinical significance of microRNAs in chronic and acute human leukemia","volume":"15","author":"Yeh","year":"2016","journal-title":"Mol Cancer"}],"container-title":["Experimental Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0301472X18307987?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0301472X18307987?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,4]],"date-time":"2025-10-04T08:33:12Z","timestamp":1759566792000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0301472X18307987"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,12]]},"references-count":37,"alternative-id":["S0301472X18307987"],"URL":"https:\/\/doi.org\/10.1016\/j.exphem.2018.09.001","relation":{},"ISSN":["0301-472X"],"issn-type":[{"value":"0301-472X","type":"print"}],"subject":[],"published":{"date-parts":[[2018,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"miR-217 sensitizes chronic myelogenous leukemia cells to tyrosine kinase inhibitors by targeting pro-oncogenic anterior gradient 2","name":"articletitle","label":"Article Title"},{"value":"Experimental Hematology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.exphem.2018.09.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 ISEH -- Society for Hematology and Stem Cells. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}